Spots Global Cancer Trial Database for Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer

Official Title: A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer

Study ID: NCT01940172

Conditions

Relapsed Epithelial Ovarian Cancer

Relapsed Primary Peritoneal Cancer

Relapsed Fallopian Tube Cancer

Interventions

Birinapant

Conatumumab

Study Description

Brief Summary: This is a dose escalation study in female subjects with relapsed ovarian cancer (including epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer). Approximately 30 to 40 subjects will be administered a combination of conatumumab and birinapant. In the initial dose-escalation stage of the study, adult female subjects will receive conatumumab in combination with increasing doses of birinapant in dose-escalation cohorts to determine the MTD of birinapant when administered with a fixed dose of conatumumab. In safety expansion stage, adult female subjects will receive conatumumab in combination with birinapant at the MTD of the combination.

Detailed Description: